OmniAb, Inc.

NasdaqGM OABI

OmniAb, Inc. Price to Book Ratio (P/B) on January 14, 2025: 1.28

OmniAb, Inc. Price to Book Ratio (P/B) is 1.28 on January 14, 2025, a -42.23% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.
  • OmniAb, Inc. 52-week high Price to Book Ratio (P/B) is 2.28 on February 27, 2024, which is 77.58% above the current Price to Book Ratio (P/B).
  • OmniAb, Inc. 52-week low Price to Book Ratio (P/B) is 1.28 on January 14, 2025, which is 0.00% below the current Price to Book Ratio (P/B).
  • OmniAb, Inc. average Price to Book Ratio (P/B) for the last 52 weeks is 1.73.
Key data
Date Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield Price to Earnings Ratio (P/E)
Market news
Loading...
NasdaqGM: OABI

OmniAb, Inc.

CEO Mr. Matthew W. Foehr
IPO Date Sept. 30, 2021
Location United States
Headquarters 5980 Horton Street
Employees 106
Sector Health Care
Industries
Description

OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.

Similar companies

VRNA

Verona Pharma plc

USD 48.44

3.75%

ITOS

iTeos Therapeutics, Inc.

USD 7.66

-1.80%

LEGN

Legend Biotech Corporation

USD 31.64

-2.65%

GLUE

Monte Rosa Therapeutics, Inc.

USD 5.56

-1.77%

ERAS

Erasca, Inc.

USD 1.93

-10.23%

OLMA

Olema Pharmaceuticals, Inc.

USD 5.14

6.20%

EWTX

Edgewise Therapeutics, Inc.

USD 27.52

8.65%

CGEM

Cullinan Oncology, Inc.

USD 10.01

-9.33%

IPSC

Century Therapeutics, Inc.

USD 0.94

-3.60%

PMVP

PMV Pharmaceuticals, Inc.

USD 1.35

-2.88%

IDYA

IDEAYA Biosciences, Inc.

USD 22.74

-1.00%

KROS

Keros Therapeutics, Inc.

USD 12.48

-2.65%

IKNA

Ikena Oncology, Inc.

USD 1.51

-1.95%

StockViz Staff

January 15, 2025

Any question? Send us an email